부산대학교 도서관

Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death before Omicron, but updated real-world evidence studies are needed. This study aimed to assess whether nirmatrelvir/ritonavir reduces the risk of COVID-19–associated hospitalization among high-risk outpatients. Methods A retrospective cohort study of outpatients with SARS-CoV-2 between March 15 and 15 October 2022, using data from the Quebec clinico-administrative databases. Outpatients treated with nirmatrelvir/ritonavir were compared with infected ones not receiving nirmatrelvir/ritonavir using propensity-score matching. Relative risk (RR) of COVID-19–associated hospitalization within 30 days was assessed using a Poisson regression. Results A total of 8402 treated outpatients were matched to controls. Regardless of vaccination status, nirmatrelvir/ritonavir treatment was associated with a 69% reduced RR of hospitalization (RR:.31; 95% CI:.28;.36; number needed to treat [NNT] = 13). The effect was more pronounced in outpatients with incomplete primary vaccination (RR:.04; 95% CI:.03;.06; NNT = 8), while no benefit was found in those with a complete primary vaccination (RR:.93; 95% CI:.78; 1.08). Subgroups analysis among high-risk outpatients with a complete primary vaccination showed that nirmatrelvir/ritonavir treatment was associated with a significant decrease in the RR of hospitalization in severely immunocompromised outpatients (RR:.66; 95% CI:.50;.89; NNT = 16) and in high-risk outpatients aged ≥70 years (RR:.50; 95% CI:.34;.74; NNT = 10) when the last dose of the vaccine was received at least 6 months ago. Conclusions Nirmatrelvir/ritonavir reduces the risk of COVID-19–associated hospitalization among incompletely vaccinated high-risk outpatients and among some subgroups of completely vaccinated high-risk outpatients. [ABSTRACT FROM AUTHOR]